Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Casirivimab/imdevimab  COVID-19 treatment studies for Casirivimab/i..  C19 studies: Casirivimab/i..  Casirivimab/i..   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ ICU admission 31% Improvement Relative Risk Oxygen therapy 7% Hospitalization -108% c19early.org/r Levey et al. Casirivimab/i.. for COVID-19 EARLY Favors casirivimab/im.. Favors control
Outcomes of pregnant patients treated with REGEN-COV during the COVID-19 pandemic
Levey et al., American Journal of Obstetrics & Gynecology MFM, doi:10.1016/j.ajogmf.2022.100673
Levey et al., Outcomes of pregnant patients treated with REGEN-COV during the COVID-19 pandemic, American Journal of Obstetrics & Gynecology MFM, doi:10.1016/j.ajogmf.2022.100673
Jun 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 86 pregnant COVID-19 patients, 36 treated with casirivimab/imdevimab, showing no significant difference in COVID-19 outcomes with treatment.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron [Liu, Sheward, Tatham, VanBlargan].
risk of ICU admission, 30.6% lower, RR 0.69, p = 1.00, treatment 1 of 36 (2.8%), control 2 of 50 (4.0%), NNT 82.
risk of oxygen therapy, 7.4% lower, RR 0.93, p = 1.00, treatment 2 of 36 (5.6%), control 3 of 50 (6.0%), NNT 225.
risk of hospitalization, 108.3% higher, RR 2.08, p = 0.15, treatment 9 of 36 (25.0%), control 6 of 50 (12.0%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Levey et al., 4 Jun 2022, retrospective, USA, peer-reviewed, 6 authors, study period March 2021 - October 2021.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperCasirivimab/i..All
Outcomes of pregnant patients treated with REGEN-COV during the COVID-19 pandemic
MD Natalie H Levey, MD Alexandra D Forrest, MD Daniella W Spielman, MApSTAT, MS; Kirk A Easley, MD, PhD Carolynn M Dude, MD Martina L Badell
American Journal of Obstetrics & Gynecology MFM, doi:10.1016/j.ajogmf.2022.100673
BACKGROUND: Pregnant patients with SARS-CoV-2 infection are at increased risk for severe disease including hospitalization, intensive care admission, ventilatory support, and death. Although pregnant patients were excluded from investigational trials for pharmacologic treatments for COVID-19 illness, the National Institutes of Health treatment guidelines state that efficacious treatments should not be withheld from pregnant patients. An infusion of casirivimab and imdevimab (REGEN-COV), a monoclonal antibody therapy, was shown to reduce the risk of COVID-19− related hospitalization or death from any cause and resolved symptoms and reduced SARS-CoV-2 viral load more rapidly than placebo. In July of 2021, the Food and Drug Administration released an Emergency Use Authorization for REGEN-COV. Although pregnant persons were not included in the original trials, given the higher risk of morbidity and mortality in the pregnant population, our institution offered REGEN-COV to our pregnant patients beginning in August of 2021. Side effects after REGEN-COV administration are rare and thought to be secondary to COVID-19 rather than REGEN-COV. OBJECTIVE: This study aimed to track safety and clinical outcomes in unvaccinated pregnant patients who received REGEN-COV and to compare these outcomes with those of a contemporary cohort of patients who tested positive for SARS-CoV-2 and were eligible but did not receive REGEN-COV. Our hypothesis was that REGEN-COV administration during pregnancy is safe, and that pregnant persons who received REGEN-COV would experience less severe COVID-19 respiratory illness, with decreased length of hospital stay, rates of intensive care unit admission, and need for oxygen and other COVID-19 therapeutics. STUDY DESIGN: This is a retrospective cohort study of pregnant patients who either tested positive for SARS-CoV-2 or had a known exposure to a COVID-19−positive person, and were therefore eligible for REGEN-COV at our institution. Within this cohort, we compared those who received REGEN-COV with those who did not between March and October of 2021 at Grady Memorial Hospital in Atlanta, Georgia. The main outcomes studied were perinatal outcomes, safety data, and the clinical course of SARS-CoV-2 infection. RESULTS: From March to October of 2021, 86 pregnant people tested positive for SARS-CoV-2 via real-time polymerase chain reaction or had a confirmed exposure. In this group, 36 received REGEN-COV and 50 did not. There were no instances of infusion rate adjustment or discontinuation, anaphylaxis, or death among individuals who received REGEN-COV. One individual experienced worsening shortness of breath >24 hours after administration, which was classified as an infusion-related reaction. There were no significant differences in perinatal outcomes, length of hospitalization, rates of intensive care unit admission, additional pharmacologic treatment for COVID-19, or oxygen requirement between the 2 groups. CONCLUSION:..
Author and article information From the Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA (Drs Levey, Forrest, Spielman, Dude, and Badell); Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA (Mr Easley). Received Mar. 30, 2022; revised May 13, 2022; accepted June 1, 2022. The authors report no conflict of interest.
References
Copin, Baum, Wloga, The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies, Cell
Deeks, Casirivimab/imdevimab: first approval, Drugs
Desisto, Wallace, Simeone, Risk for stillbirth among women with and without COVID-19 at delivery hospitalization -United States, March 2020-September 2021, MMWR Morb Mortal Wkly Rep
Gurol-Urganci, Jardine, Carroll, Maternal and perinatal outcomes of pregnant women with SARS-CoV-2 infection at the time of birth in England: national cohort study, Am J Obstet Gynecol
Halscott, Vaught, Society for Maternal-Fetal Medicine Management Considerations for Pregnant Patients With COVID-19
Hirshberg, Cooke, Oakes, Odibo, Raghuraman et al., Monoclonal antibody treatment of symptomatic COVID-19 in pregnancy: initial report, Am J Obstet Gynecol
Huang, Wang, Li, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Mayer, Vanhise, Caskey, Naqvi, Burwick, Monoclonal antibodies casirivimab and imdevimab in pregnancy for coronavirus disease 2019 (COVID-19), Obstet Gynecol
Merison, Goldman, Bomze, Subcutaneous REGEN-COV antibody combination to prevent Covid-19, N Engl J Med
Metz, Clifton, Hughes, Disease severity and perinatal outcomes of pregnant patients with coronavirus disease 2019 (COVID-19), Obstet Gynecol
O'brien, Forleo-Neto, Musser, Subcutaneous REGEN-COV Antibody Combination for Covid-19 Prevention, medRxiv, doi:10.1101/2021.06.14.21258567
Richley, Rao, Afshar, Neutralizing monoclonal antibodies for coronavirus disease 2019 (COVID-19) in pregnancy: a case series, Obstet Gynecol
Stokes, Zambrano, Anderson, Coronavirus disease 2019 case surveillance -United States, January 22, MMWR Morb Mortal Wkly Rep
Thompson, Nguyen, Noble, Aronoff, COVID-19-related disease severity in pregnancy, Am J Reprod Immunol
Wang, Berry, Moutos, Association of the Delta (B.1.617.2) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with pregnancy outcomes, Obstet Gynecol
Weinreich, Sivapalasingam, Norton, REGEN-COV antibody combination and outcomes in outpatients with Covid-19, N Engl J Med
Weinreich, Sivapalasingam, Norton, REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19, N Engl J Med
Zambrano, Ellington, Strid, Update: characteristics of symptomatic women of reproductive age with laboratoryconfirmed SARS-CoV-2 infection by pregnancy status -United States, January 22, MMWR Morb Mortal Wkly Rep
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit